Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.67 |
| ▸ | BACE1 | P56817 | 4/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6761207 | 1.00 | PTGS2 (0.67) | PTGS2BACE1ALOX5ALOX15ACHE | |
| SCHEMBL6764548 | 1.00 | PTGS2 (0.67) | PTGS2BACE1ALOX5ALOX15ACHE | |
| Ganomycin A SCHEMBL7074132 | 1.00 | PTGS2 (0.67) | PTGS2BACE1ALOX5ALOX15ACHE | |
| Ganomycin A SCHEMBL6765493 | 1.00 | PTGS2 (0.67) | PTGS2BACE1ALOX5ALOX15ACHE | |
| Ganomycin B SCHEMBL12249396 | 0.92 | BACE1 (0.65) | PTGS2BACE1ALOX5ALOX15ACHE | |
| Ganomycin B SCHEMBL30164283 | 0.92 | BACE1 (0.65) | PTGS2BACE1ALOX5ALOX15ACHE | |
| SCHEMBL6768674 | 0.92 | BACE1 (0.65) | PTGS2BACE1ALOX5ALOX15ACHE | |
| Ganomycin B SCHEMBL7074168 | 0.92 | BACE1 (0.65) | PTGS2BACE1ALOX5ALOX15ACHE | |
| Ganomycin B SCHEMBL6764577 | 0.92 | BACE1 (0.65) | PTGS2BACE1ALOX5ALOX15ACHE | |
| SCHEMBL6764592 | 0.89 | BACE1 (0.54) | PTGS2BACE1ALOX5ALOX15ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441562-B2 | Aromatic farnesyl compound and application thereof | INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2019-10-15 | — | — | US | disclosed |
| WO-2018014660-A1 | USE OF AROMATIC FARNESYL COMPOUNDS | 中国科学院微生物研究所 | 2018-01-25 | — | — | WO | disclosed |
| US-20170224651-A1 | AROMATIC FARNESYL COMPOUND AND APPLICATION THEREOF | INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20170224651-A1 | AROMATIC FARNESYL COMPOUND AND APPLICATION THEREOF | INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2017-08-10 | — | — | US | disclosed |
| WO-2016173274-A1 | AROMATIC FARNESYL COMPOUND AND APPLICATION THEREOF | 中国科学院微生物研究所 | 2016-11-03 | — | — | WO | disclosed |
| US-8466311-B2 | Neuroprotective compositions and methods | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466311-B2 | Neuroprotective compositions and methods | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466311-B2 | Neuroprotective compositions and methods | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120296112-A1 | Neuroprotective Compositions and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| US-20120296112-A1 | Neuroprotective Compositions and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| EP-2320869-A1 | SURFACTANT-FREE EMULSIONS WITH ANTI-AGING EFFECT, PRODUCTION THEREOF AND USE OF SAME | HC Berlin Pharma Ag (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2320867-A2 | PREPARATIONS BASED ON ARTEMISIA ANNUA, THE CONVERSION THEREOF INTO MICROPARTICLES AND NANOPARTICLES, AND USE OF SAME | HC Berlin Pharma Ag (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010012687-A2 | PREPARATIONS BASED ON ARTEMISIA ANNUA, THE CONVERSION THEREOF INTO MICROPARTICLES AND NANOPARTICLES, AND USE OF SAME | HC BERLIN PHARMA AG (DE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010012686-A1 | SURFACTANT-FREE EMULSIONS WITH ANTI-AGING EFFECT, PRODUCTION THEREOF AND USE OF SAME | HC BERLIN PHARMA AG (DE) | 2010-02-04 | — | — | WO | disclosed |
| US-20090042980-A1 | Neuroprotective compositions and methods | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042980-A1 | Neuroprotective compositions and methods | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-12 | — | — | US | disclosed |
| US-6726911-B1 | SOLVENT EXTRACT; MICROBIOCIDES; ENDOPEPTIDASE, ANGIOTENSIN CONVERTING ENZYME AND SERUM-MEDIATED-BINDING OF LIPOPOLYSACCHARIDE INHIBITORS | GANOMYCIN (DE) | 2004-04-27 | — | — | US | disclosed |
| EP-1158995-B1 | BIOLOGICALLY ACTIVE COMPOUNDS OF GANODERMA PFEIFFERI DMS 13239 | GANOMYCIN GES FUER BIOMEDIZINI (DE) | 2003-06-18 | — | — | EP | disclosed |
| EP-1158995-A1 | BIOLOGICALLY ACTIVE COMPOUNDS OF GANODERMA PFEIFFERI DMS 13239 | Ganomycin Gesellschaft für Biomedizinische Forschung mbH (DE) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000053207-A1 | BIOLOGICALLY ACTIVE COMPOUNDS OF $I(GANODERMA PFEIFFERI) DMS 13239 | GANOMYCIN GESELLSCHAFT FÜR BIOMEDIZINISCHE FORSCHUNG MBH ; (DE) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441562-B2 | Aromatic farnesyl compound and application thereof | HMGCR, PYGL, TGFB1 | PTGS2 1779/4885BACE1 509/4885ALOX5 2973/4885 |
| US-20090042980-A1 | Neuroprotective compositions and methods | KEAP1, NFE2L2, NQO1 | PTGS2 21/4885BACE1 176/4885ALOX5 320/4885 |
| US-20120296112-A1 | Neuroprotective Compositions and Methods | KEAP1, NFE2L2, NQO1 | PTGS2 21/4885BACE1 176/4885ALOX5 320/4885 |
| US-20170224651-A1 | AROMATIC FARNESYL COMPOUND AND APPLICATION THEREOF | HMGCR, PYGL, TGFB1 | PTGS2 1779/4885BACE1 509/4885ALOX5 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.